Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Dec 17, 6:00AM CST

BEAM : 29.01 (+8.04%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up Zacks Investment Research - Mon Dec 9, 8:34AM CST

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 29.01 (+8.04%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Beam Therapeutics Reports Successful Preclinical Data on CD117 mAb Conditioning for Base-Edited Hematopoietic Stem Cell Therapy Quiver Quantitative, Inc. - Sun Dec 8, 10:58PM CST

Beam Therapeutics announced successful long-term engraftment of base-edited stem cells using anti-CD117 mAb conditioning in preclinical studies.Quiver AI SummaryBeam Therapeutics has announced promising...

BEAM : 29.01 (+8.04%)
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Sun Dec 8, 12:45PM CST

BEAM : 29.01 (+8.04%)
Beam Therapeutics Reports Promising Results from BEACON Phase 1/2 Trial of BEAM-101 for Severe Sickle Cell Disease Quiver Quantitative, Inc. - Sat Dec 7, 8:50PM CST

All seven patients treated with BEAM-101 showed significant improvements in hemoglobin levels and resolved anemia without complications.Quiver AI SummaryBeam Therapeutics announced promising results from...

BEAM : 29.01 (+8.04%)
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Sat Dec 7, 10:30AM CST

BEAM : 29.01 (+8.04%)
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer Quiver Quantitative, Inc. - Fri Dec 6, 4:18PM CST

Beam Therapeutics appoints Sravan K. Emany as CFO to enhance financial strategy and support genetic medicine advancements.Quiver AI SummaryBeam Therapeutics Inc. has announced the appointment of Sravan...

BEAM : 29.01 (+8.04%)
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer GlobeNewswire - Fri Dec 6, 6:00AM CST

BEAM : 29.01 (+8.04%)
Beam Therapeutics Appoints Chirfi Guindo of Merck to Board of Directors Quiver Quantitative, Inc. - Wed Dec 4, 4:16PM CST

Beam Therapeutics appoints Chirfi Guindo, former Merck executive, to its board of directors to enhance strategic growth initiatives.Quiver AI SummaryBeam Therapeutics Inc. has appointed Chirfi Guindo,...

BEAM : 29.01 (+8.04%)
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader GlobeNewswire - Wed Dec 4, 6:00AM CST

BEAM : 29.01 (+8.04%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot